These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6331828)
1. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. Bannon MJ; Goedert M; Williams B Biochem Pharmacol; 1984 Sep; 33(17):2697-8. PubMed ID: 6331828 [No Abstract] [Full Text] [Related]
2. Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise. Langston JW Mov Disord; 1989; 4 Suppl 1():S15-25. PubMed ID: 2542782 [No Abstract] [Full Text] [Related]
3. Neuromelanin and its possible protective and destructive properties. Lindquist NG; Larsson BS; Lydén-Sokolowski A Pigment Cell Res; 1987; 1(3):133-6. PubMed ID: 3334086 [TBL] [Abstract][Full Text] [Related]
4. Development of new pharmacological approaches in Parkinson's disease. Carlsson A Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631 [No Abstract] [Full Text] [Related]
5. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease]. Lange KW Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447 [TBL] [Abstract][Full Text] [Related]
6. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient. Peroutka SJ; DeLanney L; Irwin I; Ison PJ; Ricaurte G; Schlegel JR; Langston JW Res Commun Chem Pathol Pharmacol; 1985 May; 48(2):163-71. PubMed ID: 3875136 [TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease: current view. Langston JW Am Fam Physician; 1987 Mar; 35(3):201-6. PubMed ID: 3103408 [TBL] [Abstract][Full Text] [Related]
8. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568 [TBL] [Abstract][Full Text] [Related]
9. Cocaine blocks the dopamine depletion induced by MPTP. Mayer RA; Jarvis MF; Wagner GC Res Commun Chem Pathol Pharmacol; 1985 Jul; 49(1):145-8. PubMed ID: 3875884 [TBL] [Abstract][Full Text] [Related]
10. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism. Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441 [No Abstract] [Full Text] [Related]
11. Parkinson's disease in 1984: an update. Lang AE; Blair RD Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779 [TBL] [Abstract][Full Text] [Related]
12. [Pethidine and parkinsonism. 1-Metyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a new neurotoxin]. Hunskår S Tidsskr Nor Laegeforen; 1986 Jan; 106(3):219-20. PubMed ID: 3485316 [No Abstract] [Full Text] [Related]
13. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985. J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069 [No Abstract] [Full Text] [Related]
14. Tissue culture model for studying MPTP toxicity to dopamine neurons. Mytilineou C; Cohen G Adv Neurol; 1987; 45():145-8. PubMed ID: 3493622 [No Abstract] [Full Text] [Related]
15. MPTP: insights into the etiology of Parkinson's disease. Langston JW Eur Neurol; 1987; 26 Suppl 1():2-10. PubMed ID: 3556187 [TBL] [Abstract][Full Text] [Related]
16. The role of MAO in MPTP toxicity--a review. Glover V; Gibb C; Sandler M J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762 [TBL] [Abstract][Full Text] [Related]